US FDA Wants To Predict ANDA Complete Response Responses
Generic industry, FDA discuss potential ways to increase transparency so agency can better estimate when – and even whether – an ANDA receiving a complete response will be returned.
You may also be interested in...
180-day exclusivity would begin when a second ANDA is approvable, rather than at first-generic's launch, a potentially major change to the Hatch-Waxman framework if implemented.
CREATES Act gets a hearing, but Judiciary committee members spend much of their time asking questions about basic concepts of FDA review.
US FDA has historically overestimated generic review performance in budget requests, but recently underestimated the number of ANDAs it expects to approve.